Detalhe da pesquisa
1.
Bismuth-Containing Quadruple Therapy for Helicobacter pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days.
Dig Dis Sci
; 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38700630
2.
Efficacy and safety of a 14-day modified concomitant therapy for refractory Helicobacter pylori infection: a pilot study.
J Gastroenterol Hepatol
; 38(12): 2097-2103, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37702104
3.
Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
Digestion
; 104(4): 249-261, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37015201
4.
Effects of enhanced education for patients with the Helicobacter pylori infection: A systematic review and meta-analysis.
Helicobacter
; 27(2): e12880, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35150600
5.
The cure rate of 10-day bismuth-containing quadruple therapy for Helicobacter pylori eradication is equivalent to 14-day: a systematic review and meta-analysis.
Clin Exp Med
; 23(4): 1033-1043, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36538198
6.
Vonoprazan is noninferior to proton pump inhibitors in bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysis.
J Dig Dis
; 24(1): 19-27, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36960538
7.
Clinical practice of Helicobacter pylori infection management by gastroenterologists in secondary and tertiary hospitals: A stratified sampling cross-sectional survey.
J Dig Dis
; 23(7): 365-375, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35880374